Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1061 to 1070 of 2606 total matches.
Isosorbide Mononitrate for Angina
The Medical Letter on Drugs and Therapeutics • Jun 26, 1992 (Issue 873)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Isosorbide mononitrate (ISMN; Ismo - Wyeth-Ayerst), an oral nitrate long available in Europe, was recently approved by the US Food and Drug Administration for prophylactic use in patients with chronic stable angina. ISMN is the major active metabolite of isosorbide dinitrate (ISDN; Isordil, and others).
Rifaximin (Xifaxan 550) for Hepatic Encephalopathy
The Medical Letter on Drugs and Therapeutics • Nov 01, 2010 (Issue 1350)
The Medical Letter®
On Drugs and Therapeutics
Volume 52 (Issue 1350)
November 1, 2010 ...
The FDA has approved a new 550-mg tablet of rifaximin (Xifaxan – Salix), a minimally absorbed oral
antibiotic, to reduce the risk of recurrent hepatic encephalopathy (HE). A 200-mg tablet has been available
for treatment of travelers’ diarrhea since 2004.
In Brief: Anktiva for Bladder Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
inbakicept with other drugs used for treatment of
NMIBC are available.
ADVERSE EFFECTS — Dysuria, hematuria ...
Nogapendekin alfa inbakicept-pmln (Anktiva –
ImmunityBio), a first-in-class interleukin-15 (IL15)
receptor agonist, has been approved by the FDA for
use with Bacillus Calmette-Guérin (BCG) for treatment
of patients with BCG-unresponsive nonmuscle
invasive bladder cancer (NMIBC) with carcinoma in
situ with or without papillary tumors. Such patients
generally undergo bladder tumor resection, followed
by intravesical BCG treatment, but treatment failure
and cancer recurrence are common. The adenoviral
vector-based intravesical gene therapy nadofaragene
firadenovec-vncg (Adstiladrin)...
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-6 doi:10.58347/tml.2024.1705e | Show Introduction Hide Introduction
FK 506 - An Investigational Immunosuppressant
The Medical Letter on Drugs and Therapeutics • Oct 04, 1991 (Issue 854)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
FK 506 (Fujisawa), an immunosuppressant similar in activity to cyclosporine (Sandimmune - Medical Letter 25:77, 1983), is currently under investigation in the USA, Europe, and Japan for prevention of organ transplant rejection.
Interferon Beta-1a for Relapsing Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Jul 19, 1996 (Issue 979)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Interferon β-1a (Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS). Interferon β-1a (Betaseron - Berlex), a recombinant analog of interferon β that differs from interferon β-1a in having a serine substituted for a cysteine and in not being glycosylated, was previously approved for this indication (Medical Letter, 35:61, 1993; BW van Oosten et al, Drugs, 49:200, 1995).
Arbutamine for Stress Testing
The Medical Letter on Drugs and Therapeutics • Jan 30, 1998 (Issue 1019)
The Medical Letter
On Drugs and Therapeutics
www.medletter.com
Published by The Medical ...
Myocardial perfusion imaging and stress echocardiography in patients who cannot exercise may require use of drugs. Arbutamine (GenESA - Gensia Automedics), a potent synthetic sympathomimetic, has recently been approved by the FDA for use with a computerized drug-delivery system in pharmacologic stress testing.
Once-a-week Alendronate (Fosamax)
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001 (Issue 1100)
The Medical Letter
On Drugs and Therapeutics
Published by The Medical Letter, Inc. • 1000 Main ...
Once-a-week formulations of alendronate (Fosamax) in 35- and 70-mg tablets have now been approved by the FDA and are being heavily promoted for prevention and treatment of postmenopausal osteoporosis. A new formulation of risedronate (Actonel) for once-a-week use is under development and may be available next year.
In Brief: Plan B OTC
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006 (Issue 1243)
Letter
®
On Drugs and Therapeutics
Volume 48 (Issue 1243)
September 11, 2006
www.medicalletter.org ...
The FDA has approved over-the-counter (OTC) sales of Plan B (Duramed), an emergency contraceptive package that contains two 0.75-mg tablets of levonorgestrel, to women ≥18 years old. Younger women still require a prescription. In one trial, two levonorgestrel 0.75-mg tablets taken 12 hours apart, the first within 72 hours after unprotected intercourse, decreased the pregnancy rate to 1%, compared to an expected rate of 8% (Task Force on Postovulatory Methods of Fertility Regulation, Lancet 1998; 352:428). How high doses of a progestin taken after coitus prevent pregnancy is unclear; they may...
Correction: Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures
The Medical Letter on Drugs and Therapeutics • Dec 17, 2007 (Issue 1276)
Letter
®
On Drugs and Therapeutics
Volume 49 (Issue 1276)
December 17, 2007
www.medicalletter.org ...
On page 100 of the article "Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures", under the section Highest-Risk Procedures, the word "rubber" should have been omitted. Placement of orthodontic rubber bands is not a highest-risk procedure that justifies prophylaxis; placement of orthodontic (metal) bands is. An orthodontic band is a metal ring that surrounds the tooth and is pressed into place causing movement in closely-spaced teeth and sometimes bleeding when the bands are placed close to the gumline.
Nonstandard Uses of Chelation Therapy
The Medical Letter on Drugs and Therapeutics • Sep 20, 2010 (Issue 1347)
The Medical Letter®
On Drugs and Therapeutics
Volume 52 (Issue 1347)
September 20, 2010 ...
Chelation therapy involves oral administration, intravenous
infusion or intramuscular injection of drugs that
increase excretion of heavy metals. The Medical Letter’s
last article on this subject found no evidence that it was
effective for treatment of cardiovascular disease. Since
then, off-label use of chelation therapy has expanded to
include treating children with autism and adults with
Alzheimer’s disease, cancer and other chronic
diseases.
Click here to view the free full article.
Click here to view the free full article.